Acepodia Reveals Initial Results from Phase 1 Study of ACE1831, the First Anti-CD20 Antibody-Linked Allogeneic Gamma Delta T Cell Treatment for Non-Hodgkin’s Lymphoma.

Sobi announced that the European Commission has approved Aspaveli® (pegcetacoplan) to treat adults with paroxysmal nocturnal haemoglobinuria and haemolytic anaemia.

Phanes Therapeutics, Inc. has entered into a clinical supply deal with Roche to test PT217 alongside an anti-PD-L1 treatment.

Neurocrine Biosciences, Inc. has launched its Phase 1 clinical trial, marking the first time humans are being evaluated.

Biotheryx, Inc. revealed that their Investigational New Drug application for BTX-9341, an innovative bifunctional degrader targeting cyclin-dependent kinase 4/6 (CDK4/6).

Neurogene revealed promising safety results from its Phase 1/2 study on NGN-401, a gene therapy for Rett Syndrome.

Merus Reveals FDA Approval and Expedited Assessment of BLA for Zeno to Manage NRG1+ Lung and Pancreatic Cancer.

Positive Phase 2 Results for XyloCor Therapeutics’ Main Candidate XC001 Announced at SCAI 2024 and in the Journal Circulation: Cardiovascular Interventions.

Context Therapeutics has received FDA approval for its IND application, initiating a Phase 1 clinical trial of CTIM-76.

Remix Therapeutics has started dosing the first participants in a pair of Phase 1 studies. These trials are testing REM-422 in treating Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS).

Alpha-9 Oncology reports initial dosing of the first participant in a phase 1 trial for A9-3202, targeting locally advanced or metastatic melanoma patients.

Atsena Therapeutics Reveals Encouraging Results from Initial Group in Phase 1/2 Study of ATSN-201 Gene Treatment for X-linked Retinoschisis (XLRS).